Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Apellis Pharmaceuticals Inc (APLS) USD0.0001

Sell:$32.41 Buy:$32.47 Change: $0.01 (0.03%)
Market closed |  Prices as at close on 23 September 2021 | Switch to live prices |
Change: $0.01 (0.03%)
Market closed |  Prices as at close on 23 September 2021 | Switch to live prices |
Change: $0.01 (0.03%)
Market closed |  Prices as at close on 23 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company’s lead product candidate is APL-2. APL-2 is Phase III clinical trials developed for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. It is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. The Company is developing APL-9 for intravenous administration in systemic indications.

Contact details

100 Fifth Avenue
United States
+1 (617) 9775700

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.82 billion
Shares in issue:
87.00 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Cedric Francois
    President, Chief Executive Officer, Co-Founder, Director
  • Pascal Deschatelets
    Co-Founder, Chief Scientific Officer
  • Timothy Sullivan
    Chief Financial Officer, Treasurer
  • Nur Nicholson
    Chief Technical Operations Officer
  • James Chopas
    Chief Accounting Officer, Vice President, Corporate Controller
  • Nicole Perry
    Vice President - Accounting, Treasurer
  • David Watson
    General Counsel
  • Federico Grossi
    Chief Medical Officer
  • Lukas Scheibler
    Chief Innovation Officer
  • Adam Townsend
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.